MX2022008091A - Derivado de tetrahidroisoquinolina triciclica, metodo de preparacion del mismo y aplicacion del mismo en medicina. - Google Patents

Derivado de tetrahidroisoquinolina triciclica, metodo de preparacion del mismo y aplicacion del mismo en medicina.

Info

Publication number
MX2022008091A
MX2022008091A MX2022008091A MX2022008091A MX2022008091A MX 2022008091 A MX2022008091 A MX 2022008091A MX 2022008091 A MX2022008091 A MX 2022008091A MX 2022008091 A MX2022008091 A MX 2022008091A MX 2022008091 A MX2022008091 A MX 2022008091A
Authority
MX
Mexico
Prior art keywords
tricyclic
preparation
method therefor
medicine
application
Prior art date
Application number
MX2022008091A
Other languages
English (en)
Inventor
Feng He
Weikang Tao
Fanglong Yang
Jingjing Yan
Xiqian Zhang
Xing Fan
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2022008091A publication Critical patent/MX2022008091A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0836—Compounds with one or more Si-OH or Si-O-metal linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un derivado de tetrahidroisoquinolina tricíclico, un método de preparación del mismo y una aplicación del mismo en medicina. En particular, la presente invención se relaciona con un derivado de tetrahidroisoquinolina tricíclica representado por la fórmula general (I), un método de preparación para el mismo y una composición farmacéutica que comprende dicho derivado, un uso del mismo como modulador del receptor de estrógeno y un uso del mismo en la preparación de un fármaco para tratar enfermedades o trastornos mediados o dependientes de receptores de estrógenos. Los sustituyentes en la fórmula general (I) son los mismos que los definidos en la invención. (ver Fórmula).
MX2022008091A 2020-01-10 2021-01-08 Derivado de tetrahidroisoquinolina triciclica, metodo de preparacion del mismo y aplicacion del mismo en medicina. MX2022008091A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202010025118 2020-01-10
CN202010036802 2020-01-14
CN202010273891 2020-04-09
CN202010680491 2020-07-15
CN202010819555 2020-08-14
CN202010971693 2020-09-16
PCT/CN2021/070826 WO2021139756A1 (zh) 2020-01-10 2021-01-08 三环四氢异喹啉类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2022008091A true MX2022008091A (es) 2022-07-11

Family

ID=76787742

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008091A MX2022008091A (es) 2020-01-10 2021-01-08 Derivado de tetrahidroisoquinolina triciclica, metodo de preparacion del mismo y aplicacion del mismo en medicina.

Country Status (11)

Country Link
US (1) US20230140679A1 (es)
EP (1) EP4089094A4 (es)
JP (1) JP2023509944A (es)
KR (1) KR20220125272A (es)
CN (2) CN116731064A (es)
AU (1) AU2021205156A1 (es)
BR (1) BR112022013322A2 (es)
CA (1) CA3164166A1 (es)
MX (1) MX2022008091A (es)
TW (1) TW202140495A (es)
WO (1) WO2021139756A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022307207A1 (en) 2021-07-09 2024-02-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Salt types of tricyclic tetrahydro isoquinoline derivative
TW202317539A (zh) 2021-07-15 2023-05-01 大陸商四川海思科製藥有限公司 芳氨基衍生物***受體調節劑及其用途
WO2024052518A1 (en) 2022-09-09 2024-03-14 Sanofi Substituted tetrahydrocyclohepta[e]indole derivatives, processes for their preparation and therapeutic uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
CA2673736A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2013073875A1 (ko) 2011-11-15 2013-05-23 한국화학연구원 신규한 항바이러스성 피롤로피리딘 유도체 및 이의 제조방법
US20150336977A1 (en) 2013-01-07 2015-11-26 B.G. Negev Technologies And Applications Ltd. Coumestan, Coumestrol, Coumestan Derivatives and Processes of Making the Same and Uses of Same
IN2013MU00646A (es) 2013-03-04 2015-06-26 Intas Pharmaceuticals Ltd
WO2014135834A1 (en) 2013-03-05 2014-09-12 Cipla House Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator
CN105121413B (zh) 2013-03-14 2018-09-14 赛拉根医药股份有限公司 多环***受体调节剂及其用途
EP2981530B1 (en) 2013-04-04 2020-02-12 The Administrators of the Tulane Educational Fund Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
CA2911859A1 (en) 2013-05-28 2014-12-04 Astrazeneca Ab Chemical compounds
WO2015092634A1 (en) * 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
AU2016279330B2 (en) * 2015-06-16 2020-05-14 Jiangsu Hengrui Medicine Co., Ltd. Piperidine derivative and preparation method and pharmaceutical use thereof
WO2017174757A1 (en) * 2016-04-08 2017-10-12 F. Hoffmann-La Roche Ag Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
WO2019002442A1 (en) * 2017-06-29 2019-01-03 Astrazeneca Ab CHEMICAL COMPOUNDS
EP3696178B1 (en) * 2017-11-14 2022-04-06 Kind Pharmaceutical Heterocyclic compound and application thereof in medicine
CN111770924B (zh) * 2018-04-04 2023-05-09 深圳福沃药业有限公司 用于治疗乳腺癌的***受体降解剂
WO2019228443A1 (en) * 2018-05-30 2019-12-05 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Selective estrogen receptor downregulators and uses thereof

Also Published As

Publication number Publication date
CN114746424B (zh) 2023-06-16
TW202140495A (zh) 2021-11-01
BR112022013322A2 (pt) 2022-09-20
CN116731064A (zh) 2023-09-12
WO2021139756A1 (zh) 2021-07-15
US20230140679A1 (en) 2023-05-04
KR20220125272A (ko) 2022-09-14
JP2023509944A (ja) 2023-03-10
EP4089094A1 (en) 2022-11-16
CN114746424A (zh) 2022-07-12
AU2021205156A1 (en) 2022-07-14
CA3164166A1 (en) 2021-07-15
EP4089094A4 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
MX2022008091A (es) Derivado de tetrahidroisoquinolina triciclica, metodo de preparacion del mismo y aplicacion del mismo en medicina.
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
MX2020000268A (es) Agonista de fxr.
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2023015533A (es) Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.
MX2020008422A (es) Regulador derivado de esteroides, metodo para prepararlos y usos de los mismos.
FR3037958B1 (fr) Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HK1095815A1 (zh) 細胞粘着調節劑
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
MX2018007844A (es) Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo.
TW200621262A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
MX2022007155A (es) Derivados de cromano novedosos que tienen actividad de degradacion de receptor de estrogeno y usos de los mismos.
GEP20125538B (en) 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
MX2021011823A (es) Derivado pirroloheterociclico, metodo de preparacion del mismo y su aplicacion en medicina.
SG11201806438UA (en) Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases
MX2020013785A (es) Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo.
PH12019501724A1 (en) Estrogen receptor modulators
GEP20125707B (en) Chromane derivatives as trpv3 modulators
MX2023011166A (es) Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina.
JO2749B1 (en) Indole-2-Wen derivatives bilaterally substituted at position 3, their preparation and therapeutic application
NZ515891A (en) New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents
MX2024001352A (es) Inhibidor novedoso de la poli(adp-ribosa) polimerasa y uso del mismo.
ZA202200660B (en) Process for the preparation of ridinilazole and crystalline forms thereof
MX2023000868A (es) Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo.